PL3397967T3 - Kompozycje i sposoby do wykrywania i leczenia raka przełyku - Google Patents
Kompozycje i sposoby do wykrywania i leczenia raka przełykuInfo
- Publication number
- PL3397967T3 PL3397967T3 PL17700483T PL17700483T PL3397967T3 PL 3397967 T3 PL3397967 T3 PL 3397967T3 PL 17700483 T PL17700483 T PL 17700483T PL 17700483 T PL17700483 T PL 17700483T PL 3397967 T3 PL3397967 T3 PL 3397967T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- detection
- treatment
- methods
- esophageal cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307189 | 2015-12-31 | ||
| EP16305139 | 2016-02-05 | ||
| EP17700483.5A EP3397967B1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
| PCT/EP2017/050037 WO2017114976A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3397967T3 true PL3397967T3 (pl) | 2021-06-28 |
Family
ID=57821946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17700483T PL3397967T3 (pl) | 2015-12-31 | 2017-01-02 | Kompozycje i sposoby do wykrywania i leczenia raka przełyku |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11789021B2 (pl) |
| EP (2) | EP3397967B1 (pl) |
| JP (2) | JP7018885B2 (pl) |
| KR (2) | KR102197478B1 (pl) |
| CN (2) | CN108700589A (pl) |
| AU (2) | AU2017204686B2 (pl) |
| BR (1) | BR112018013272A2 (pl) |
| CA (2) | CA3193481C (pl) |
| EA (1) | EA037032B1 (pl) |
| ES (2) | ES2861587T3 (pl) |
| PL (1) | PL3397967T3 (pl) |
| SG (1) | SG11201805263TA (pl) |
| WO (1) | WO2017114976A1 (pl) |
| ZA (1) | ZA201804142B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| DK3720879T3 (da) * | 2017-12-05 | 2022-06-20 | Progastrine Et Cancers S A R L | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer |
| US20200390913A1 (en) | 2017-12-08 | 2020-12-17 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| EP3759492A1 (en) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| EP3765853B1 (en) * | 2018-03-13 | 2024-05-01 | Creatv Microtech, Inc. | Methods for monitoring treatment response and disease progression in subjects using circulating cells |
| KR102167078B1 (ko) * | 2019-07-19 | 2020-10-16 | (주)파즈코리아 | 혈액 샘플 이송 장치 |
| WO2021081498A1 (en) * | 2019-10-24 | 2021-04-29 | The Johns Hopkins University | Compositions and methods for detecting and treating esophageal cancer |
| JP7287532B2 (ja) * | 2020-08-04 | 2023-06-06 | 王子ホールディングス株式会社 | トイレットロール |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2004536835A (ja) * | 2001-07-09 | 2004-12-09 | アフトン コーポレーション | 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止 |
| EP2567974A3 (en) | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| JP2009529915A (ja) * | 2006-03-20 | 2009-08-27 | ゾーマ テクノロジー リミテッド | ガストリン物質に対して特異的なヒト抗体および方法 |
| US7854932B2 (en) * | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US20110085986A1 (en) * | 2009-10-13 | 2011-04-14 | Pomila Singh | Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| WO2011116954A2 (en) | 2010-03-24 | 2011-09-29 | Bioréalités S.A.S. | Prophylaxis of colorectal and gastrointestinal cancer |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| FI20145550A7 (fi) * | 2014-06-13 | 2015-12-14 | Biohit Oyj | Gastriini-17 käyttö biomarkkerina atrofiselle gastriitille ja usealle sen seurauksena kohonneelle riskille |
| WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
-
2017
- 2017-01-02 BR BR112018013272-1A patent/BR112018013272A2/en not_active IP Right Cessation
- 2017-01-02 EP EP17700483.5A patent/EP3397967B1/en active Active
- 2017-01-02 CA CA3193481A patent/CA3193481C/en active Active
- 2017-01-02 ES ES17700483T patent/ES2861587T3/es active Active
- 2017-01-02 PL PL17700483T patent/PL3397967T3/pl unknown
- 2017-01-02 CA CA3009785A patent/CA3009785A1/en active Pending
- 2017-01-02 EP EP20217589.9A patent/EP3848709B1/en active Active
- 2017-01-02 AU AU2017204686A patent/AU2017204686B2/en not_active Ceased
- 2017-01-02 WO PCT/EP2017/050037 patent/WO2017114976A1/en not_active Ceased
- 2017-01-02 KR KR1020187020013A patent/KR102197478B1/ko active Active
- 2017-01-02 SG SG11201805263TA patent/SG11201805263TA/en unknown
- 2017-01-02 KR KR1020207037405A patent/KR102430893B1/ko active Active
- 2017-01-02 CN CN201780013902.0A patent/CN108700589A/zh active Pending
- 2017-01-02 EA EA201891527A patent/EA037032B1/ru unknown
- 2017-01-02 JP JP2018534930A patent/JP7018885B2/ja active Active
- 2017-01-02 CN CN202610219611.8A patent/CN122307124A/zh active Pending
- 2017-01-02 US US16/067,208 patent/US11789021B2/en active Active
- 2017-01-02 ES ES20217589T patent/ES3003287T3/es active Active
-
2018
- 2018-06-20 ZA ZA201804142A patent/ZA201804142B/en unknown
-
2020
- 2020-03-31 AU AU2020202296A patent/AU2020202296B2/en active Active
-
2022
- 2022-01-31 JP JP2022013712A patent/JP7363007B2/ja active Active
-
2023
- 2023-09-15 US US18/468,096 patent/US20240085423A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296080B1 (en) | Method for treating cancer | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL258688A (en) | Compositions and methods for viral cancer neoepitopes | |
| IL255261A0 (en) | Methods for treating cancer | |
| IL253162A0 (en) | Compositions and methods for treatment and detection of cancers | |
| IL256025A (en) | Methods of diagnosing and treating cancer | |
| PL3288581T3 (pl) | Sposób leczenia nowotworu | |
| BR112017011771A2 (pt) | métodos e composições para o tratamento de câncer | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| PL3443350T3 (pl) | Sposoby monitorowania i leczenia nowotworu | |
| PL3377516T3 (pl) | Kompozycja do leczenia nowotworu | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| DK3277842T3 (da) | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer | |
| EP3245225A4 (en) | Compositions and methods for treatment and detection of cancers | |
| PT3142637T (pt) | Formulações e métodos de tratamento de queratina | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| PL3200815T3 (pl) | Sposoby i kompozycje do leczenia nowotworu | |
| SI3594238T1 (sl) | Sestavki protiteles za zdravljenje tumorja | |
| PL3189074T3 (pl) | Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| IL254876A0 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| IL253160B (en) | Cancer markers and methods of use thereof | |
| PT3458052T (pt) | Tratamento combinado do cancro | |
| ZA201804142B (en) | Compositions and methods for detecting and treating esophageal cancer |